<\/span><\/h2>\nApremilast (Otezla\u00ae; Celgene, NJ, USA) is a small oral medicationmolecule<\/span> inhibitor enzyme<\/span> phosphodiesterase 4, which plays an important role in chronic<\/span> inflammation<\/span> associated with psoriasis.<\/p>\nIn July 2019, apremilast was also approved by the FDA for the treatment of the mouth. ulcers<\/span> associated with Beh\u00e7et's disease.<\/p>\n<\/span>What is apremilast used for?<\/span><\/h2>\nIn September 2014, the United States Food and Drug Administration (FDA) approved the use of apremilast in patients with license plate<\/span> psoriasis. It was approved for use in New Zealand in psoriasis in November 2016.<\/p>\nApremilast is approved for the treatment of plaque psoriasis in patients:<\/p>\n
\n- who did not respond or were intolerant to treatment with etanercept (Enbrel\u00ae) and adalimumab (Humira\u00ae)<\/li>\n
- those with a history of hepatitis<\/span> B, hepatitis C, demyelinating disease, malignancy<\/span>, chronic infection<\/span> (e.g HIV<\/span>) or congestive heart failure<\/li>\n
- long-term patients systemic<\/span> corticosteroid therapy.<\/li>\n<\/ul>\n
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for apremilast for:<\/p>\n
\n- treatment of moderate to severe chronic plaque psoriasis in adult patients who have not responded or who have contraindication<\/span> a, or are intolerant of other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light (PUVA).<\/li>\n<\/ul>\n
It has been reported to be particularly effective in palmoplantar<\/span> psoriasis.<\/p>\nApremilast also proved to be effective for the treatment of oral administration. ulceration<\/span> in Beh\u00e7et's disease.<\/p>\n\n
\n
\n
\n<\/div><\/div><\/div><\/div>\n
<\/span>How does apremilast work in psoriasis?<\/span><\/h2>\n\n- The plaque formation of psoriasis is believed to be caused by deregulated<\/span> immune activity within the skin.<\/li>\n
- Is deregulation<\/span> can lead to an increase in the production of proinflammatory<\/span> cytokines<\/span> how tumor<\/span> necrosis<\/span> factor (TNF) -\u03b1, interleukin<\/span> (IL) -17 and IL-23 that promote chronic inflammation of the epidermis<\/span> and proliferation<\/span> of keratinocytes<\/span>.<\/li>\n
- These changes cause redness, itching, epidermal<\/span> thickening and scaly<\/span> plates<\/span>.<\/li>\n
- PDE4 is the predominant intracellular<\/span> enzyme that degrades cyclic adenosine monophosphate (cAMP) within a variety of inflammatory<\/span> cells, including eosinophils<\/span>, neutrophils<\/span><\/span>, macrophages<\/span>, T cells<\/span>and monocytes<\/span>.<\/li>\n
- PDE4 degrades cAMP in its inactive AMP form, thus allowing these immune cells<\/span> to produce elevated levels of pro-inflammatory cytokines and decreased levels of anti-inflammatory<\/span> cytokines<\/li>\n
- Apremilast is an inhibitor of PDE4 and prevents the degradation of cAMP to AMP, suppressing the production of pro-inflammatory cytokines including tumor necrosis factor TNF-\u03b1, IL-17 and interferon (IFN) -\u03b3 and promoting the production of antiinflammatory mediators<\/span> like IL-10.<\/li>\n<\/ul>\n
<\/span>How is apremilast given?<\/span><\/h2>\nThe recommended dose of apremilast is 30 mg twice a day. To reduce the risk of gastrointestinal symptoms, the recommended dose is adjusted according to the following schedule:<\/p>\n
Day 1: 10 mg in the morning
Day 2: 10 mg in the morning and 10 mg in the afternoon.
Day 3: 10 mg in the morning and 20 mg in the afternoon.
Day 4: 20 mg in the morning and 20 mg in the afternoon.
Day 5: 20 mg in the morning and 30 mg in the afternoon.
Day 6 and following: 30 mg twice a day.<\/p>\n
For patients with severe renal<\/span> Deterioration, the recommended dose is 30 mg once a day, adjusted using only the morning schedule, as above.<\/p>\n